We are live on ! Find out more
TCM

TCG Crossover Management Portfolio holdings

AUM $4.16B
1-Year Est. Return 983.43%
This Fund
S&P 500
This Quarter Est. Return
+83.13%
1 Year Est. Return
+983.43%
3 Year Est. Return
+3,012.95%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$567M
AUM Growth
+$233M
Cap. Flow
+$110M
Cap. Flow %
19.49%
Top 10 Hldgs %
79.55%
Holding
26
New
5
Increased
7
Reduced
4
Closed
5

Top Buys

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$27M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$25.2M
3
VTYX
Ventyx Biosciences
VTYX
+$23.3M
4
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$18.8M
5
KALV
KalVista Pharmaceuticals
KALV
+$18.2M

Top Sells

Rank Stock Value
1
ALLK
Allakos
ALLK
+$10.1M
2
AKUS
Akouos Inc
AKUS
+$9.13M
3
TNGX icon
Tango Therapeutics
TNGX
+$4.24M
4
VRDN icon
Viridian Therapeutics
VRDN
+$4.16M
5
DNTH icon
Dianthus Therapeutics
DNTH
+$3M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ISEE
1
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$110M 19.43%
5,141,118
+1,263,215
+33% +$27M
MDGL icon
2
Madrigal Pharmaceuticals
MDGL
$12.3B
$83.6M 14.76%
288,054
+258,054
+860% +$25.2M
COGT icon
3
Cogent Biosciences
COGT
$6.02B
$42M 7.41%
3,631,042
+150,000
+4% +$1.86M
CBAY
4
DELISTED
Cymabay Therapeutics
CBAY
$37M 6.53%
5,905,400
– –
GERN icon
5
Geron
GERN
$970M
$36.8M 6.49%
15,187,073
+3,071,147
+25% +$6.88M
SLN
6
Silence Therapeutics
SLN
$834M
$32.1M 5.67%
2,104,875
– –
JBIO
7
Jade Biosciences
JBIO
$1.33B
$31.7M 5.59%
30,894
+3,478
+13% +$2.53M
VRDN icon
8
Viridian Therapeutics
VRDN
$2.61B
$28.7M 5.07%
983,610
-180,390
-15% -$4.16M
VTYX
9
DELISTED
Ventyx Biosciences
VTYX
$25.8M 4.56%
+787,231
New +$23.3M
KALV
10
DELISTED
KalVista Pharmaceuticals
KALV
$23M 4.05%
+3,395,495
New +$18.2M
VECT
11
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$20.2M 3.57%
+2,333,300
New +$18.8M
ACRS icon
12
Aclaris Therapeutics
ACRS
$885M
$18M 3.18%
1,144,939
– –
KURA icon
13
Kura Oncology
KURA
$1.13B
$17.7M 3.12%
1,423,642
+75,000
+6% +$1.09M
IMVT icon
14
Immunovant
IMVT
$8.51B
$15.2M 2.68%
+854,853
New +$10.8M
TYRA icon
15
Tyra Biosciences
TYRA
$1.49B
$15.1M 2.67%
1,989,103
+1,043,396
+110% +$7.38M
MLTX icon
16
MoonLake Immunotherapeutics
MLTX
$1.28B
$10.5M 1.85%
1,000,000
– –
TRDA icon
17
Entrada Therapeutics
TRDA
$273M
$7.91M 1.4%
584,955
-57,234
-9% -$1M
MRUS
18
DELISTED
Merus
MRUS
$4.64M 0.82%
300,000
– –
CABA icon
19
Cabaletta Bio
CABA
$529M
$4.5M 0.79%
+486,795
New +$1.77M
ALPN
20
DELISTED
Alpine Immune Sciences Inc
ALPN
$1.86M 0.33%
253,069
-1,500
-0.6% -$9.59K
ELEV
21
DELISTED
Elevation Oncology
ELEV
$274K 0.05%
288,390
-266,610
-48% -$271K
ALLK
22
DELISTED
Allakos
ALLK
– –
-1,643,500
Closed -$10.1M
DNTH icon
23
Dianthus Therapeutics
DNTH
$5.92B
– –
-132,758
Closed -$3M
TNGX icon
24
Tango Therapeutics
TNGX
$3.94B
– –
-1,172,250
Closed -$4.24M
ZLAB icon
25
Zai Lab
ZLAB
$2.93B
– –
-72,777
Closed -$2.49M
1
2

Similar funds

GCM
Gates Capital Management New York $4.16B AUM 21% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
CIC
Chilton Investment Company Stamford, Connecticut $4.17B AUM 1.75% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $4.15B AUM 31.06% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $4.15B AUM
CAM
Crake Asset Management London, United Kingdom $4.18B AUM 13.97% 1-Year Est. Return
JFG
JMG Financial Group Downers Grove, Illinois $4.14B AUM 21.49% 1-Year Est. Return

TCG Crossover Management's Q4 2022 Portfolio in Review

As of Q4 2022, TCG Crossover Management held 26 positions worth $567M, up 70% from $333M the previous quarter. Its ten largest holdings account for 80% of the portfolio.

TCG Crossover Management deployed $110M of net new capital in Q4 2022, opening 5 new positions and adding to 7 existing holdings. Its largest new stake was Ventyx Biosciences: 787,231 shares worth $25.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Viridian Therapeutics, an estimated $4.16M trimmed.

  • TCG Crossover Management's largest Q4 2022 buy was Ventyx Biosciences: 787,231 shares worth $25.8M.
  • TCG Crossover Management added most to IVERIC bio, Inc. Common Stock in Q4 2022, an estimated $27M increase.
  • TCG Crossover Management's biggest Q4 2022 reduction was Viridian Therapeutics, cutting an estimated $4.16M.
  • TCG Crossover Management fully exited Allakos in Q4 2022, selling an estimated $10.1M.
  • TCG Crossover Management's ten largest holdings make up 80% of its $567M portfolio in Q4 2022.
  • TCG Crossover Management opened 5 new positions and closed 5 in Q4 2022.
  • TCG Crossover Management's portfolio value rose 70% quarter-over-quarter to $567M.

Based on TCG Crossover Management's 13F filing for Q4 2022, filed 14 Feb 2023.